Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4252MR)

This product GTTS-WQ4252MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4252MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15595MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ1996MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ15449MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA U3-1287
GTTS-WQ3462MR IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AZD8895
GTTS-WQ8871MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ5022MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ1766MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ15596MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW